BioLife Solutions (NASDAQ:BLFS - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect BioLife Solutions to announce earnings of $0.05 per share and revenue of $29.13 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.88. The company had revenue of $28.47 million during the quarter, compared to analysts' expectations of $27.80 million. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%. On average, analysts expect BioLife Solutions to post $0.03 EPS for the current fiscal year and $0.16 EPS for the next fiscal year.
BioLife Solutions Price Performance
BioLife Solutions stock opened at $38.61 on Thursday. The company has a market cap of $1.89 billion, a P/E ratio of 33.28 and a beta of 1.82. The business has a 50-day simple moving average of $37.46 and a two-hundred day simple moving average of $27.81. BioLife Solutions has a 52-week low of $17.86 and a 52-week high of $39.76.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on BLFS shares. TD Cowen downgraded shares of BioLife Solutions from a "buy" rating to a "hold" rating and cut their price objective for the company from $33.00 to $31.00 in a research report on Wednesday, July 22nd. Zacks Research cut shares of BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 21st. HC Wainwright downgraded shares of BioLife Solutions from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $32.00 to $31.00 in a report on Thursday, July 23rd. Lake Street Capital lowered shares of BioLife Solutions from a "buy" rating to a "hold" rating and cut their target price for the company from $33.00 to $31.00 in a report on Wednesday, July 22nd. Finally, William Blair set a $31.00 price target on BioLife Solutions in a research report on Thursday, July 23rd. One analyst has rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, BioLife Solutions has an average rating of "Hold" and an average target price of $31.38.
Check Out Our Latest Research Report on BLFS
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.
The company's portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
